Kangstem Biotech Co. Ltd (217730) — Cash Flow-to-Debt Ratio
Kangstem Biotech Co. Ltd (217730) has a Cash Flow-to-Debt Ratio of -0.33x as of September 2025, meaning its operating cash flow of ₩-3.81 Billion could theoretically repay 0% of its total liabilities (₩11.60 Billion) in one year. See 217730 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kangstem Biotech Co. Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Kangstem Biotech Co. Ltd across 10 annual periods. Also explore Kangstem Biotech Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kangstem Biotech Co. Ltd (2015–2024)
Year-by-year debt coverage analysis for Kangstem Biotech Co. Ltd. For market capitalisation and broader financial context, see 217730 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.48x | ₩-18.99 Billion | ₩12.80 Billion | ▼ -230.2% |
| 2023 | -0.45x | ₩-16.50 Billion | ₩36.74 Billion | ▲ +20.6% |
| 2022 | -0.57x | ₩-18.86 Billion | ₩33.33 Billion | ▼ -16.8% |
| 2021 | -0.48x | ₩-16.99 Billion | ₩35.07 Billion | ▼ -6.9% |
| 2020 | -0.45x | ₩-13.99 Billion | ₩30.89 Billion | ▼ -46.0% |
| 2019 | -0.31x | ₩-13.32 Billion | ₩42.92 Billion | ▲ +31.0% |
| 2018 | -0.45x | ₩-11.48 Billion | ₩25.50 Billion | ▲ +5.2% |
| 2017 | -0.47x | ₩-10.65 Billion | ₩22.44 Billion | ▼ -48.9% |
| 2016 | -0.32x | ₩-7.80 Billion | ₩24.46 Billion | ▲ +68.6% |
| 2015 | -1.01x | ₩-3.80 Billion | ₩3.75 Billion | — |